Inhibition of GPX4 enhances CDK4/6 inhibitor and endocrine therapy activity in breast cancer

M. T. Herrera-Abreu, J. Guan, U. Khalid, J. Ning, M. R. Costa, J. Chan, Q. Li, J-P. Fortin, W. R. Wong, P. Perampalam, A. Biton, W. Sandoval, J. Vijay, M. Hafner, R. Cutts, G. Wilson, J. Frankum, T. I. Roumeliotis, J. Alexander, O. Hickman, R. Brough, S. Haider, J. Choudhary, C. J. Lord, A. Swain, C. Metcalfe () and N. C. Turner ()
Additional contact information
M. T. Herrera-Abreu: The Institute of Cancer Research
J. Guan: 1 DNA Way
U. Khalid: The Institute of Cancer Research
J. Ning: Institute of Cancer Research
M. R. Costa: 1 DNA Way
J. Chan: 1 DNA Way
Q. Li: 1 DNA Way
J-P. Fortin: 1 DNA Way
W. R. Wong: 1 DNA Way
P. Perampalam: ProCogia Inc. under contract to Hoffmann-La Roche Limited
A. Biton: 1 DNA Way
W. Sandoval: 1 DNA Way
J. Vijay: Roche Informatics
M. Hafner: 1 DNA Way
R. Cutts: The Institute of Cancer Research
G. Wilson: The Institute of Cancer Research
J. Frankum: The Institute of Cancer Research
T. I. Roumeliotis: The Institute of Cancer Research
J. Alexander: The Institute of Cancer Research
O. Hickman: The Institute of Cancer Research
R. Brough: The Institute of Cancer Research
S. Haider: The Institute of Cancer Research
J. Choudhary: The Institute of Cancer Research
C. J. Lord: The Institute of Cancer Research
A. Swain: Institute of Cancer Research
C. Metcalfe: 1 DNA Way
N. C. Turner: The Institute of Cancer Research

Nature Communications, 2024, vol. 15, issue 1, 1-19

Abstract: Abstract CDK4/6 inhibition in combination with endocrine therapy is the standard of care for estrogen receptor (ER+) breast cancer, and although cytostasis is frequently observed, new treatment strategies that enhance efficacy are required. Here, we perform two independent genome-wide CRISPR screens to identify genetic determinants of CDK4/6 and endocrine therapy sensitivity. Genes involved in oxidative stress and ferroptosis modulate sensitivity, with GPX4 as the top sensitiser in both screens. Depletion or inhibition of GPX4 increases sensitivity to palbociclib and giredestrant, and their combination, in ER+ breast cancer models, with GPX4 null xenografts being highly sensitive to palbociclib. GPX4 perturbation additionally sensitises triple negative breast cancer (TNBC) models to palbociclib. Palbociclib and giredestrant induced oxidative stress and disordered lipid metabolism, leading to a ferroptosis-sensitive state. Lipid peroxidation is promoted by a peroxisome AGPAT3-dependent pathway in ER+ breast cancer models, rather than the classical ACSL4 pathway. Our data demonstrate that CDK4/6 and ER inhibition creates vulnerability to ferroptosis induction, that could be exploited through combination with GPX4 inhibitors, to enhance sensitivity to the current therapies in breast cancer.

Date: 2024
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-024-53837-7 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-53837-7

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-024-53837-7

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().